CarsonAllaria Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

CarsonAllaria Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25	Closed	-$428	–	298
2025 Q2	$428	Hold	25	–	–	﹤0.01%	346
2025 Q1	$1.6K	Hold	25	–	–	﹤0.01%	333
2024 Q4	$3.04K	Sell	25 -25	-50%	-$3.06K	﹤0.01%	300
2024 Q3	$6.25K	Sell	50 -26	-34%	-$3.59K	﹤0.01%	294
2024 Q2	$12K	Hold	76	–	–	0.01%	240
2024 Q1	$9.84K	Hold	76	–	–	0.01%	250
2023 Q4	$7.33K	Hold	76	–	–	0.01%	240
2023 Q3	$9.21K	Buy	76 +25	+49%	+$2.83K	0.01%	214
2023 Q2	$5.84K	Hold	51	–	–	﹤0.01%	257
2023 Q1	$7.03K	Buy	+51	New	+$6.62K	0.01%	235

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CarsonAllaria Wealth Management's SRPT Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 25 shares — an estimated $428 sold.

CarsonAllaria Wealth Management first reported a position in SRPT in Q1 2023 and held it in 10 quarters. The position peaked at $12K in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

CarsonAllaria Wealth Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 25 Sarepta Therapeutics shares in Q3 2025, an estimated $428.
CarsonAllaria Wealth Management first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 10 quarters.
CarsonAllaria Wealth Management's Sarepta Therapeutics position peaked at $12K in Q2 2024.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.